Abstract
Ticagrelor is an orally active, reversibly bind of the P2Y12 receptor that can prevent ADP-mediated platelet activation and has a faster onset of action than clopidogrel. A stability-indicating HPLC method for the determination of ticagrelor in coated tablets was developed and validated. Chromatographic analysis was performed in a Shimadzu liquid chromatograph, equipped with Phemomenex® C18 column (250 x 4.6 mm, 5 μm), using a mobile phase composed of acetonitrile: water with 0.5% triethylamine (57:43 v/v) pH 7.0, at 0.7 ml/min flow rate and injection volume of 20 μl. Under the conditions established, the method demonstrated to be specific, without interference from formulation excipients, stability- indicating, linear (r = 0.9990) in the concentration range of 45.0 to 105.0 μg/ml, precise (RSD=0.71), accurate (99.61% of mean recovery) and robust. It can be successfully applied to ticagrelor tablets quality control, being adequate for routine analysis.
Keywords: Antiplatelet, HPLC, quality control, stability-indicating assay, tablets, ticagrelor.
Current Pharmaceutical Analysis
Title:Determination of the New Antiplatelet Agent Ticagrelor in Tablets by Stability-Indicating HPLC Method
Volume: 10 Issue: 4
Author(s): Caren Gobetti, Rubia Lazzaretti Pereira, Andreas Sebastian Loureiro Mendez and Cássia Virginia Garcia
Affiliation:
Keywords: Antiplatelet, HPLC, quality control, stability-indicating assay, tablets, ticagrelor.
Abstract: Ticagrelor is an orally active, reversibly bind of the P2Y12 receptor that can prevent ADP-mediated platelet activation and has a faster onset of action than clopidogrel. A stability-indicating HPLC method for the determination of ticagrelor in coated tablets was developed and validated. Chromatographic analysis was performed in a Shimadzu liquid chromatograph, equipped with Phemomenex® C18 column (250 x 4.6 mm, 5 μm), using a mobile phase composed of acetonitrile: water with 0.5% triethylamine (57:43 v/v) pH 7.0, at 0.7 ml/min flow rate and injection volume of 20 μl. Under the conditions established, the method demonstrated to be specific, without interference from formulation excipients, stability- indicating, linear (r = 0.9990) in the concentration range of 45.0 to 105.0 μg/ml, precise (RSD=0.71), accurate (99.61% of mean recovery) and robust. It can be successfully applied to ticagrelor tablets quality control, being adequate for routine analysis.
Export Options
About this article
Cite this article as:
Gobetti Caren, Pereira Lazzaretti Rubia, Mendez Sebastian Loureiro Andreas and Garcia Virginia Cássia, Determination of the New Antiplatelet Agent Ticagrelor in Tablets by Stability-Indicating HPLC Method, Current Pharmaceutical Analysis 2014; 10 (4) . https://dx.doi.org/10.2174/1573412910666140610211656
DOI https://dx.doi.org/10.2174/1573412910666140610211656 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research Omega-3 Polyunsaturated Fatty Acids: Their Potential Role in Blood Pressure Prevention and Management
Current Vascular Pharmacology Statin Related Memory Dysfunction in a Nigerian Woman: A Case Report
Current Drug Safety A Comprehensive Review on Anti-obesity Potential of Medicinal Plants and their Bioactive Compounds
Current Traditional Medicine The Nervous System as a Critical Regulator of Immune Responses Underlying Allergy
Current Pharmaceutical Design Cannabinoids: Between Neuroprotection and Neurotoxicity
Current Drug Targets - CNS & Neurological Disorders Biomarkers of Atrial Fibrillation in Hypertension
Current Medicinal Chemistry Electrocardiogram in Andersen-Tawil Syndrome. New Electrocardiographic Criteria for Diagnosis of Type-1 Andersen-Tawil Syndrome
Current Cardiology Reviews Origin and Biological Significance of Shed-Membrane Microparticles
Endocrine, Metabolic & Immune Disorders - Drug Targets Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Neuroprotective and Neurorestorative Effects of Epo and VEGF: Perspectives for New Therapeutic Approaches to Neurological Diseases
Current Pharmaceutical Design Epilepsy in Cerebrovascular Diseases: A Narrative Review
Current Neuropharmacology Biomechanical Stress-induced Signaling in Smooth Muscle Cells: An Update
Current Vascular Pharmacology Editorial (Hot Topic: Diagnostic Decision-making for Cardiac Emergencies)
Current Cardiology Reviews Synthetic Androgens as Designer Supplements
Current Neuropharmacology Therapeutic Potential of Modulating microRNAs in Atherosclerotic Vascular Disease
Current Vascular Pharmacology Testosterone Deficiency Syndrome: Cellular and Molecular Mechanism of Action
Current Aging Science The Protective Effect of Vitexin Compound B-1 on Rat Cerebral I/R Injury through a Mechanism Involving Modulation of miR-92b/NOX4 Pathway
CNS & Neurological Disorders - Drug Targets Effects of Spices (Saffron, Rosemary, Cinnamon, Turmeric and Ginger) in Alzheimer's Disease
Current Alzheimer Research Single-cell RNA Sequencing: In-depth Decoding of Heart Biology and Cardiovascular Diseases
Current Genomics